Federal Supply Schedule 36F79721D0166

Biocryst Pharmaceuticals Inc., a biotechnology company specializing in rare disease treatments, holds a multiple-award Federal Supply Schedule (FSS) contract (36F79721D0166) with a $1.25 million ceiling under GSA Schedule 61-IB for Pharmaceuticals and Drugs. This IDV serves as the parent vehicle for numerous delivery orders from the U.S. Department of Veterans Affairs (VA) to supply Biocryst's pharmaceutical products, such as ORLADEYO for hereditary angioedema and RAPIVAB for influenza treatment. Biocryst also holds a single-award $10 million Blanket Purchase Agreement (BPA) with the VA specifically for the expedited procurement of ORLADEYO and RAPIVAB through May 2025. These contracting mechanisms facilitate the VA's efficient acquisition of critical medications to support healthcare services for veterans. Biocryst has received multiple firm fixed-price delivery orders under its FSS contract from various VA regional networks, ranging from $29,649.88 to $69.4 million, with no set-aside designations. The company's pharmaceutical products are delivered to locations across the United States, including Earth City, Missouri, Durham, North Carolina, and Roseburg, Oregon, to meet the VA's medication requirements.

Overall, Biocryst Pharmaceuticals is a key supplier of specialty pharmaceuticals to the U.S. federal government, particularly the Department of Veterans Affairs, through its portfolio of IDV contracts. The company's FSS contract and BPA enable streamlined procurement processes and pre-negotiated pricing for critical drugs used in veteran healthcare services. Biocryst's contracting activities demonstrate its significant role in supporting the VA's mission to provide comprehensive medical care for the nation's military veterans.